IN THIS ISSUE

Richard Mark Kirkner

Sabrina Corlette, Georgetown University

State and federal regulators want to make sure that access to providers isn’t impinged, but maintenance of the lists is too often shoddy.
Legislation & Regulation
Richard Mark Kirkner

©StockMonkeys.com

The public wants it. Presidential candidates are talking about it. Will Congress make it happen?
Medication Management
Thomas Reinke
Two companies, two drugs for Duchenne muscular dystrophy in the expedited approval process. The stakes are high, especially for patients and their families.
Tomorrow’s Medicine
Thomas Morrow, MD
This newest asthma medication—two decades in development—offers millions new hope. Good stuff, say many, but costly.
Viewpoint
Andrew J. Haig, MD
As costs for treating back pain skyrocket, some stakeholders turn to a team approach featuring this little-used specialist.
News & Commentary
Frank Diamond